TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

FTC challenge to Edwards JenaValve acquisition could delay FDA approval
Edwards Lifesciences asked the U.S. Federal Trade Commission (FTC) this week to dismiss the complaint against the company's acquisition of JenaValve this week. A healthcare market analysis firm also said the FTC actions will likely impact the timing of an FDA clearance of the Trilogy heart valve.
TAVR in patients with bicuspid aortic valve stenosis: Does device type matter?
More and more care teams are treating BAV stenosis with TAVR instead of surgical aortic valve replacement. Self-expanding and balloon-expandable valves appear to have their own benefits—as well as their own risks.
Hemodynamic deterioration 1 year after TAVR found in 6% of patients
Hemodynamic valve deterioration after one year was more common in patients with a small aortic annulus. In fact, receiving a larger valve was linked to a “protective” quality that appeared to help keep the risk of such complications to a minimum.
FTC challenges ‘anticompetitive’ TAVR acquisition
The FTC is working to stop Edwards Lifesciences from completing its acquisition of JenaValve. Edwards, however, is not backing down.
Exploring the value of same-day permanent pacemaker implantation after TAVR
Temporary pacemakers are typically used for at least 24 hours before care teams consider implanting a permanent device. New research out of Canada suggests it may make sense in certain scenarios to go straight to the permanent pacemaker.

FTC challenge to Edwards JenaValve acquisition could delay FDA approval

Edwards Lifesciences asked the U.S. Federal Trade Commission (FTC) this week to dismiss the complaint against the company's acquisition of JenaValve this week. A healthcare market analysis firm also said the FTC actions will likely impact the timing of an FDA clearance of the Trilogy heart valve.

TAVR in patients with bicuspid aortic valve stenosis: Does device type matter?

More and more care teams are treating BAV stenosis with TAVR instead of surgical aortic valve replacement. Self-expanding and balloon-expandable valves appear to have their own benefits—as well as their own risks.

cardiologists going through the certification process

Hemodynamic deterioration 1 year after TAVR found in 6% of patients

Hemodynamic valve deterioration after one year was more common in patients with a small aortic annulus. In fact, receiving a larger valve was linked to a “protective” quality that appeared to help keep the risk of such complications to a minimum.

FTC challenges ‘anticompetitive’ TAVR acquisition

The FTC is working to stop Edwards Lifesciences from completing its acquisition of JenaValve. Edwards, however, is not backing down.

Exploring the value of same-day permanent pacemaker implantation after TAVR

Temporary pacemakers are typically used for at least 24 hours before care teams consider implanting a permanent device. New research out of Canada suggests it may make sense in certain scenarios to go straight to the permanent pacemaker.

cardiologists heart doctors heart research heart data

Colchicine reduces risk of some TAVR complications

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.

Edwards Lifesciences loses TAVR leader to robotics firm, announces replacement

The change comes at a momentous time for the company's TAVR portfolio, which made history in May by receiving the very first FDA approval for treating asymptomatic severe AS.

Toby Rogers, MD, Medstar, discusses a new dedicated device for BASILICA used in TAVR.

New device could make it easier than ever for cardiologists to perform BASILICA before TAVR

Toby Rogers, MD, PhD, noted that BASILICA is a fairly complex procedure. Using this advanced technology, however, could make it easier to perform and improve patient access.